HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

The issue of comorbidity in the treatment of panic.

Abstract
Both depression and panic disorder are found commonly in community surveys and it is not unexpected that there should be a co-occurrence of these disorders in some patients. However, recent data suggest that there is a greater clustering of depression among panic disorder patients and panic disorder among depressed patients than one might expect by chance alone. For example, further analysis of data from the National Comorbidity Survey indicates that there is a history of major depression in 55.6% of subjects with lifetime panic disorder and that 21.6 % of depressed patients experience a panic attack at some time in their lives. The high incidence of comorbidity of panic and major depressive disorders emphasizes the value of pharmacotherapy with a broad-spectrum agent that can treat the symptoms of comorbid psychiatric disorders effectively. Of the therapeutic options available, there is mounting evidence that selective serotonin reuptake inhibitors (SSRIs) represent reasonable monotherapy for patients with comorbid depression and panic disorder, based on the equivalent efficacy and improved side-effect profiles compared with other classes of antidepressant. The clinical relevance of differences in the pharmacokinetic and clinical profiles of SSRIs have been discussed in the context of treatment strategies for the patient with comorbid depression and panic disorder.
AuthorsD L Dunner
JournalInternational clinical psychopharmacology (Int Clin Psychopharmacol) Vol. 13 Suppl 4 Pg. S19-24 (Apr 1998) ISSN: 0268-1315 [Print] ENGLAND
PMID9690961 (Publication Type: Journal Article, Review)
Chemical References
  • Antidepressive Agents
  • Serotonin Uptake Inhibitors
Topics
  • Antidepressive Agents (adverse effects, therapeutic use)
  • Comorbidity
  • Depressive Disorder, Major (diagnosis, drug therapy, epidemiology)
  • Humans
  • Panic Disorder (diagnosis, drug therapy, epidemiology)
  • Primary Health Care (statistics & numerical data)
  • Serotonin Uptake Inhibitors (adverse effects, therapeutic use)
  • Treatment Outcome
  • World Health Organization

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: